Roger Adsett Sells 2,370 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 2,370 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the transaction, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Adsett also recently made the following trade(s):

• On Wednesday, April 1st, Roger Adsett sold 88,060 shares of Insmed stock. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80.

Insmed Trading Down 10.2%

NASDAQ:INSM traded down $10.70 during midday trading on Friday, hitting $94.22. 7,955,757 shares of the company traded hands, compared to its average volume of 2,804,548. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The firm’s fifty day moving average is $131.53 and its 200-day moving average is $155.38. The firm has a market capitalization of $20.42 billion, a P/E ratio of -16.39 and a beta of 0.79. Insmed, Inc. has a 12-month low of $70.57 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the previous year, the company earned ($1.42) EPS. The firm’s revenue for the quarter was up 229.7% compared to the same quarter last year. On average, sell-side analysts predict that Insmed, Inc. will post -2.56 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on INSM. Mizuho upped their target price on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Guggenheim lowered their price target on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a report on Friday, May 8th. Stifel Nicolaus increased their price objective on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Finally, Leerink Partners upped their target price on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $210.50.

Institutional Investors Weigh In On Insmed

Large investors have recently modified their holdings of the business. Norges Bank acquired a new position in Insmed during the 4th quarter valued at approximately $506,625,000. Vanguard Group Inc. increased its position in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares during the period. RTW Investments LP raised its stake in Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after acquiring an additional 1,758,321 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd acquired a new stake in Insmed during the 2nd quarter worth about $153,389,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.